Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ \ Origin: Appendix 5 \ \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$ 

ABN 55 00:	9 686 435	
	ne entity) give ASX the following	g information.
	1 - All issues st complete the relevant sections (attac	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	Up to 859,712 fully paid ordinary shares
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares to be issued under a non-renounceable pro-rata rights issue announced on 23 May 2016 (Rights Issue)

Name of entity

Capilano Honey Limited (Company)

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$19.50 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The funds raised under the Rights Issue (after payment of costs) will be used to strengthen the financial and commercial position of the Company. Refer to section 4.9 of the Offer Document.
ба	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
бс	Number of *securities issued without security holder approval under rule 7.1	Nil

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of +securities issued	N/A	
ou	with security holder approval under rule 7.1A		
бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	+Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.		ted on the basis of the tout in section 2 of the
	ı		
8	Number and +class of all +securities quoted on ASX (including the +securities in section a if applicable)	Number 9,456,833	+Class Fully paid ordinary shares Foundation share
	section 2 if applicable)	•	i odridation snate

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class	
N/A	N/A	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Company has declared a fully franked dividend for FY 2016 of \$0.40 per fully paid ordinary share with record date at 30 June 2016. Any future dividends to be declared in respect of the increased capital will depend on the profits earned.

### Part 2 - Pro rata issue

11 Is security holder approval required?

No

Is the issue renounceable or non-renounceable?

Non-renounceable

Ratio in which the \*securities will be offered

One (1) new fully paid ordinary share for every ten (10) fully paid ordinary shares held as at the Record Date

<sup>+</sup>Class of <sup>+</sup>securities to which the offer relates

Fully paid ordinary shares

15 \*Record date to determine entitlements

7:00 p.m. Brisbane time on 26 May 2016

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

No

17 Policy for deciding entitlements in relation to fractions

Fractional entitlements will be rounded up to the nearest whole number

<sup>+</sup> See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	All countries other than Australia, New Zealand, Hong Kong and Singapore
19	Closing date for receipt of	5:00 p.m. (Brisbane time) on 20 June 2016
	acceptances or renunciations	
20	Names of any underwriters	Canaccord Genuity (Australia) Limited (ACN 075 071 466) Morgans Corporate Limited (ACN 010 539 607)
21	Amount of any underwriting fee or commission	Underwriting commission of 2.25% of the maximum amount to be raised under the Rights Issue ( <b>Underwritten Amount</b> ) and management fee of 0.75% of the Underwritten Amount
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	31 May 2016
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B New issue announcement

29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	27 June 2016
34 (a)	ed only complete this section if you are ap  Type of *securities (tick one)  *Securities described in Part	
(b)	All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entiti	es that have ticked box 34(a)	
Addi	ional securities forming a nev	v class of securities
Tick to docum	indicate you are providing the informatents	tion or
35	If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders	
36		y securities, a distribution schedule of the additional umber of holders in the categories
L Soo a	hanter to for defined terms	

<sup>+</sup> See chapter 19 for defined terms.

1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over A copy of any trust deed for the additional +securities 37 Entities that have ticked box 34(b) 38 Number of \*securities for which N/A <sup>+</sup>quotation is sought +Class of +securities for which N/A 39 quotation is sought Do the \*securities rank equally in N/A 40 all respects from the +issue date with an existing \*class of quoted \*securities? If the additional \*securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution OT interest payment N/A 41 Reason for request for quotation Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another \*security, clearly identify that other \*security)

<sup>+</sup> See chapter 19 for defined terms.

Number and \*class of all \*securities quoted on ASX (including the \*securities in clause 38)

Number	+Class
N/A	N/A
	l

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(<del>Directo</del>r/Company secretary)

Date: 33/5/16

Print name:

Annette Zbosnik

== == == ==

04/03/2013

Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1 and Part 2 - Not applicable

Appendix 3B Page 10

<sup>+</sup> See chapter 19 for defined terms.